Knolens SLR14 Jan 2026
The pharmaceutical industry has never stood still, but today, the pace of innovation and competition is redefining how clinical strategy must operate. The days of developing a drug in isolation, confident that the sheer science would secure market dominance, are long gone.
KnolAI10 Jan 2026
Clinical development teams spend 40+ hours per month manually extracting competitor trial data, time that could be spent on strategic planning. Yet 62% of protocol amendments stem from avoidable competitive blind spots identified too late.
KnolScape08 Jan 2026
Protocol amendments cost pharma companies $535K on average and delay trials by 6+ months. Yet 40% of amendments stem from avoidable design flaws that benchmarking could have caught.
Pienomial29 Dec 2025
The pharmaceutical and life sciences sector is in a huge transition. You can't deny the efficiency AI offers, but here’s the sticking point: unlike most other industries, pharma can’t afford to rush. Every bit of evidence produced from trial data to value dossiers must survive intense scrutiny from regulators, HTA agencies, and global payers. So, the future isn't just about deploying AI; it's about being strategic and adopting truly compliant AI in healthcare.
systematic literature review28 Dec 2025
The pharma industry sits right at the intersection of breakthrough science and ironclad regulation. There’s practically zero room for error. AI promises to turbocharge drug discovery, speed up clinical trials, and simplify those exhausting regulatory submissions. But here’s the thing: there's a huge chasm between general-purpose AI and the truly reliable AI for life sciences needed for GxP environments.
Pienomial27 Dec 2025
The pharmaceutical industry has a timing problem. We spend years developing a molecule. We spend months designing a clinical trial. We spend weeks compiling a systematic literature review. But the market does not wait for our timeline.
Knolens SLR26 Dec 2025
We are living through a data paradox. We have access to more clinical information than at any point in human history, yet the ability to verify that information has never been more fragile.
Pienomial25 Dec 2025
The life sciences sector produces huge volumes of clinical, regulatory and scientific data. Most organisations find themselves struggling because their evidence lives in separate tools, databases, and team environments.
Pienomial24 Dec 2025
Market Access teams work in rapidly evolving environments where payer demands, clinical changes and competition change rapidly. To build compelling value stories, teams must act as soon as information reaches them.
KnolAI23 Dec 2025
Healthcare and life sciences are producing scientific information at an unprecedented pace. Every year, millions of new publications emerge across clinical trials, real‑world studies, regulatory decisions, conference abstracts, and health economics research.
Knolens SLR22 Dec 2025
Health technology assessments, regulatory submissions, and evidence-based decision frameworks depend on comprehensive and systematically evaluated scientific literature.
KnolScapes18 Dec 2025
The field of drug development is entering a new era characterised by data-driven decision-making, predictive modelling and advanced computational science. Over the last 20 years, costs to bring a new therapy to market have increased by close to a tenfold increase, typically referred to as Eroom’s Law.
Systematic Literature Reviews15 Dec 2025
In the modern life sciences landscape, data is no longer the bottleneck; the bottleneck is synthesis. Pharmaceutical companies, specifically Health Economics and Outcomes Research (HEOR)
